Positive News SentimentPositive NewsNASDAQ:OCS Oculis (OCS) Stock Forecast, Price & News $11.34 -0.41 (-3.49%) (As of 03:58 PM ET) Add Compare Share Share Today's Range$11.25▼$11.4050-Day Range$11.00▼$14.0052-Week Range$6.26▼$14.50Volume2,304 shsAverage Volume20,997 shsMarket Capitalization$412.66 millionP/E RatioN/ADividend YieldN/APrice Target$33.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Oculis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside196.9% Upside$33.40 Price TargetShort InterestHealthy0.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.71) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector749th out of 976 stocksPharmaceutical Preparations Industry351st out of 447 stocks 3.5 Analyst's Opinion Consensus RatingOculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.40, Oculis has a forecasted upside of 196.9% from its current price of $11.25.Amount of Analyst CoverageOculis has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.16% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently increased by 8.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCS. Previous Next 2.7 News and Social Media Coverage News SentimentOculis has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oculis this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for OCS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 14.28% of the stock of Oculis is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Oculis are expected to grow in the coming year, from ($2.71) to ($1.40) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Oculis (NASDAQ:OCS) StockOculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.Read More OCS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCS Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comAnalysts Set Oculis Holding AG (NASDAQ:OCS) PT at $33.40September 24, 2023 | barrons.comOculis Holding AG WtOctober 3, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 14, 2023 | investing.comOculis Holding AG (OCS)September 11, 2023 | finance.yahoo.comOculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial PhaseAugust 30, 2023 | msn.comB of A Securities Maintains Oculis Holding (OCS) Buy RecommendationAugust 30, 2023 | markets.businessinsider.comExpert Ratings for Oculis HoldingAugust 30, 2023 | finance.yahoo.comOculis to Present at Upcoming September Investor ConferencesOctober 3, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 29, 2023 | finanznachrichten.deOculis Holding AG: Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company UpdateAugust 29, 2023 | finance.yahoo.comOculis Reports Q2 and First Half 2023 Financial Results and Provides Company UpdateAugust 17, 2023 | msn.comOculis: Swiss Pharma With Excellent Data, Unclear FundamentalsAugust 8, 2023 | finance.yahoo.comOCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract SurgeryAugust 4, 2023 | msn.comHC Wainwright & Co. Reiterates Oculis Holding (OCS) Buy RecommendationAugust 3, 2023 | msn.comOculis enrols first patient in trial of its OCS-01 eye dropsAugust 2, 2023 | finance.yahoo.comFirst Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular EdemaJuly 27, 2023 | finance.yahoo.comOculis Announces to Present at Upcoming August Investor ConferencesJuly 19, 2023 | finance.yahoo.comOculis to Present at OIS Retina Innovation SummitJuly 14, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Oculis Holding (OCS)June 15, 2023 | benzinga.comOculis Announces Partial Exercise of Underwriters' Option to Purchase Additional Ordinary SharesJune 15, 2023 | msn.comBofA starts Oculis at buy rating, bullish on lead eye drug OCS-01June 15, 2023 | finance.yahoo.comOculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and EconomicsJune 15, 2023 | finance.yahoo.comOculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary SharesJune 8, 2023 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Oculis Holding (OCS)See More Headlines Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Email Address OCS Company Calendar Last Earnings8/29/2023Today10/03/2023Next Earnings (Estimated)12/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCS CUSIPN/A CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$33.40 High Stock Price Forecast$64.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+184.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.22 Quick Ratio7.22 Sales & Book Value Annual Sales$960,000.00 Price / Sales445.40 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares36,390,000Free FloatN/AMarket Cap$427.58 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Riad Sherif M.B.A. (Age 55)M.D., CEO & Director Ms. Sylvia Cheung (Age 48)Chief Financial Officer Mr. Weibo Ding (Age 52)Global COO & GM of China Dr. Bastian Dehmel (Age 52)Chief Devel. Officer & Head of Devel. Dr. Joanne Chang M.D. (Age 62)Ph.D., Head of Medical Affairs & Chief Medical Officer Mr. Páll Ragnar Jóhannesson (Age 42)Chief Strategy Officer Dr. Fang LiSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsMineralys TherapeuticsNASDAQ:MLYSNurix TherapeuticsNASDAQ:NRIXLiquidiaNASDAQ:LQDAProcaps GroupNASDAQ:PROCMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInstitutional OwnershipBarclays PLCBought 3,602 shares on 9/21/2023Ownership: 0.010%Ergoteles LLCBought 20,000 shares on 8/14/2023Ownership: 0.055%Barclays PLCBought 3,602 shares on 8/3/2023Ownership: 0.010%View All Institutional Transactions OCS Stock - Frequently Asked Questions Should I buy or sell Oculis stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCS shares. View OCS analyst ratings or view top-rated stocks. What is Oculis' stock price forecast for 2023? 7 equities research analysts have issued 12 month price objectives for Oculis' stock. Their OCS share price forecasts range from $23.00 to $64.00. On average, they expect the company's stock price to reach $33.40 in the next twelve months. This suggests a possible upside of 184.3% from the stock's current price. View analysts price targets for OCS or view top-rated stocks among Wall Street analysts. How have OCS shares performed in 2023? Oculis' stock was trading at $9.2122 at the start of the year. Since then, OCS stock has increased by 27.5% and is now trading at $11.75. View the best growth stocks for 2023 here. When is Oculis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023. View our OCS earnings forecast. How were Oculis' earnings last quarter? Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings data on Tuesday, August, 29th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.09. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.28 million. What is Oculis' stock symbol? Oculis trades on the NASDAQ under the ticker symbol "OCS." How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Oculis' stock price today? One share of OCS stock can currently be purchased for approximately $11.75. How much money does Oculis make? Oculis (NASDAQ:OCS) has a market capitalization of $427.58 million and generates $960,000.00 in revenue each year. How can I contact Oculis? The official website for the company is www.oculis.com. The company can be reached via phone at 41-21-711-3970 or via email at ir@oculis.com. This page (NASDAQ:OCS) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.